 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of [0m
[34mgastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of [0m
[32mgastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ATENOLOL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients with suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m [0m
[31mafter the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or conventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood [0m
[31mpressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight percent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain [0m
[31mto entry was [0m[1;31m5.0[0m[31m ± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol group were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg [0m
[31mevery [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes after the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice[0m
[31mdaily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history characteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree [0m
[31matrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the vascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This[0m
[31mabsolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. ATENOLOL: pharmacodynamics: [0m[1;31m05[0m[31m level. The absolute difference translates into a proportional reduction of [0m[1;31m15[0m[31m% [0m
[1;31m([0m[1;31m3.89[0m[31m-[0m[1;31m4.57[0m[31m/[0m[1;31m4.57[0m[31m = [0m[1;31m-0.15[0m[1;31m)[0m[31m. The [0m[1;31m95[0m[31m% confidence limits are [0m[1;31m1[0m[31m%[0m[1;31m-27[0m[31m%. Most of the difference was attributed to mortality in days [0m[1;31m0[0m[31m to [0m[1;31m1[0m[31m [0m[1;31m([0m[31matenolol - [0m[1;31m121[0m[31m deaths; control - [0m[1;31m171[0m[31m deaths[0m[1;31m)[0m[31m. Despite the large size [0m
[31mof the ISIS-[0m[1;31m1[0m[31m trial, it is not possible to identify clearly subgroups of patients most likely or least likely to benefit from early treatment with atenolol. Good clinical judgment suggests, however, [0m
[31mthat patients who are dependent on sympathetic stimulation for maintenance of adequate cardiac output and blood pressure are not good candidates for beta blockade. Indeed, the trial protocol reflected[0m
[31mthat judgment by excluding patients with blood pressure consistently below [0m[1;31m100[0m[31m mm Hg systolic. ATENOLOL: pharmacodynamics: The overall results of the study are compatible with the possibility that [0m
[31mpatients with borderline blood pressure [0m[1;31m([0m[31mless than [0m[1;31m120[0m[31m mm Hg systolic[0m[1;31m)[0m[31m, especially if over [0m[1;31m60[0m[31m years of age, are less likely to benefit. The mechanism through which atenolol improves survival in [0m
[31mpatients with definite or suspected acute myocardial infarction is unknown, as is the case for other beta blockers in the postinfarction setting. Atenolol, in addition to its effects on survival, has [0m
[31mshown other clinical benefits including reduced frequency of ventricular premature beats, reduced chest pain, and reduced enzyme elevation.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the ATENOLOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The adverse reactions section [0m
[32mlists gastrointestinal effects such as diarrhea and nausea, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization.[0m

[32mSOURCE: ATENOLOL label[0m
[32mEXTRACT_START_END: ATENOLOL: adverse_reactions: GASTROINTESTINAL Diarrhea [0m[1;32m2[0m[32m [0m[1;32m0[0m[32m [0m[32m...[0m[32m nausea [0m[1;32m4[0m[32m [0m[1;32m1[0m[32m [0m[1;32m3[0m[32m [0m[1;32m1[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the [0m
[34mATENOLOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The adverse reactions section lists gastrointestinal effects such as [0m
[34mdiarrhea and nausea, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization.[0m

[34mSOURCE: ATENOLOL label[0m
[34mEXTRACT_START_END: ATENOLOL: adverse_reactions: GASTROINTESTINAL Diarrhea [0m[1;34m2[0m[34m [0m[1;34m0[0m[34m [0m[34m...[0m[34m nausea [0m[1;34m4[0m[34m [0m[1;34m1[0m[34m [0m[1;34m3[0m[34m [0m[1;34m1[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the ATENOLOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label does list gastrointestinal [0m
[32meffects such as diarrhea and nausea, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ATENOLOL increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the ATENOLOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label does list gastrointestinal [0m
[34meffects such as diarrhea and nausea, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ATENOLOL increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ATENOLOL increases or decreases the risk of gastrointestinal ulcer hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the ATENOLOL label does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. The label does list gastrointestinal [0m
[31meffects such as diarrhea and nausea, but there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for ATENOLOL does not specifically mention an increase or decrease in the risk of gastrointestinal ulcer hospitalization. While the label lists gastrointestinal effects such as diarrhea [0m
[32mand nausea, there is no direct mention of gastrointestinal ulcers or their potential to lead to hospitalization. Therefore, based on the available FDA label data, we cannot determine if ATENOLOL has [0m
[32man effect on the risk of gastrointestinal ulcer hospitalization.[0m
